Oncolytics Biotech’s (ONCY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY – Free Report) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2030 earnings at $0.01 EPS.

Separately, Weiss Ratings raised shares of Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, November 10th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Oncolytics Biotech has an average rating of “Hold” and a consensus price target of $5.00.

Read Our Latest Research Report on ONCY

Oncolytics Biotech Stock Down 10.4%

Shares of Oncolytics Biotech stock opened at $0.35 on Thursday. The stock has a market capitalization of $47.66 million, a P/E ratio of -1.09 and a beta of 1.26. The company has a 50-day simple moving average of $0.54 and a 200 day simple moving average of $0.81. Oncolytics Biotech has a 12-month low of $0.33 and a 12-month high of $1.30.

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). On average, equities analysts anticipate that Oncolytics Biotech will post -0.30 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new position in Oncolytics Biotech in the 1st quarter valued at $608,000. Connective Capital Management LLC acquired a new stake in shares of Oncolytics Biotech in the 2nd quarter valued at $176,000. Fifth Third Bancorp increased its stake in shares of Oncolytics Biotech by 87.9% in the 3rd quarter. Fifth Third Bancorp now owns 85,526 shares of the company’s stock valued at $57,000 after buying an additional 40,000 shares during the period. International Assets Investment Management LLC increased its stake in shares of Oncolytics Biotech by 129.6% in the 3rd quarter. International Assets Investment Management LLC now owns 462,008 shares of the company’s stock valued at $310,000 after buying an additional 260,748 shares during the period. Finally, Susquehanna International Group LLP raised its position in shares of Oncolytics Biotech by 224.6% during the second quarter. Susquehanna International Group LLP now owns 134,129 shares of the company’s stock worth $127,000 after acquiring an additional 92,806 shares during the last quarter. Institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech News Summary

Here’s some of the latest news about ONCY:

  • Positive Sentiment: HC Wainwright raised its EPS forecasts for 2026–2029, projecting narrower losses, and maintained its Buy rating. This is a modestly positive analyst signal. HC Wainwright Reaffirms Buy Rating for Oncolytics Biotech
  • Negative Sentiment: Zacks Research lowered its estimates for 2026–2028, including a wider projected FY2026 loss of $0.31 per share versus its prior $0.27 estimate. The more cautious outlook tempers HC Wainwright’s revisions. Oncolytics Biotech analyst estimates

Oncolytics Biotech Company Profile

(Get Free Report)

Oncolytics Biotech is a clinical-stage biotechnology company developing cancer immunotherapies. Its lead product candidate, pelareorep, is an investigational virus-based therapy intended to activate the immune system against cancer. The company is studying pelareorep in combination with other treatments, including chemotherapy and immunotherapies, for cancers such as breast cancer and pancreatic cancer. Pelareorep is not an approved treatment. Based in Canada, Oncolytics conducts clinical development through research and trials involving patients and collaborators in multiple regions.

Further Reading

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.